Neurochem's New Agent Will Become the Clinical Gold Standard for the Treatment of Alzheimer's Disease in 2008
Posted on: Wednesday, 7 March 2007, 09:02 CST
WALTHAM, Mass., March 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Neurochem's new agent will become the clinical gold standard for the treatment of Alzheimer's disease in 2008. According to the new report entitled Alzheimer's Disease: Turning Physician Insight into Projected Patient Share, the drug, currently known as tramiprosate (also called NC-758), will provide greater efficacy than Eisai/Pfizer's Aricept, the current gold standard.
"As a disease-modifying drug, tramiprosate promises to delay cognitive, functional, and overall clinical decline longer than Aricept, a much-needed improvement over currently available treatments, which address only the symptoms of Alzheimer's disease," said Andrea Witt, Ph.D., director at Decision Resources.
About Alzheimer's Disease: Turning Physician Insight into Projected Patient Share
Alzheimer's Disease: Turning Physician Insight into Projected Patient Share covers the current and future state of the Alzheimer's disease drug market. The report includes:
-- More than 3,000 physician responses that define drug attributes that drive prescription now and in the future. -- Clinical end point tradeoffs that are most influential to physicians. -- Areas of unmet need with highest potential. -- Benchmark trial results for specific drug opportunities. -- Patient share potential for emerging therapies and target product profiles. -- Decision Resources proprietary analysis of commercial factors that accelerate or constrain a drug's market potential. -- Promotion: DTC spend, detailing intensity. -- Reimbursement: formulary tier, prior approval restriction, quantity limits. -- Labeling: black box warnings, approved patient segments, contraindications. -- Competition: order of entry, pricing, generic entry, pipeline sales forecast. -- Medical practice: decision trees, treating physician type, line of therapy. -- Comparisons of the key clinical attributes of current and emerging therapies in the areas of efficacy, safety, and delivery. -- Analysis and supporting data that identifies the clinical "Gold Standard" now and over the next ten years. -- Key insights as to which clinical end points have the greatest influence on physician decision-making.
The report can be purchased by contacting Decision Resources. Members of the media may request a complimentary copy or an interview with an analyst.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563, oremarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium
- Novartis/Schering-Plough's Drug Will Replace AstraZeneca's Symbicort as Decision Resources' Clinical Gold Standard by 2012 for the Treatment of Asthma
- An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the United States
- Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development
- A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's Disease Drug Market
- A Drug With Efficacy Superior to That of Memantine Would Earn Up to a 50% Patient Share in the Moderate-to-Severe Alzheimer's Disease Drug Market
- Decision Resources Defines a Hypothetical Parkinson's Disease Drug That Would Earn 25% Patient Share
- The Alliance for Aging Research Unveils New Resource for Family Caregivers of Alzheimer's Patients
- GW Medical Technologies' New Blood Test for Alzheimer's Disease Seeks Future Test Candidates; Patients and Physicians Needed for Breakthrough Test
- Study: Drug May Help Alzheimer's Patients
 |
 |
User Comments (0)
RSS Feeds